Commercial Strategy and Client Portfolio Growth for Life Sciences
Many life sciences service providers depend on referrals, a founder's network or a handful of accounts. That can work for a while, but it rarely builds a resilient business. Corstrate provides chief commercial level advisory to help CROs, CDMOs and biotechs diversify their client portfolio, enter new markets and put a durable growth model in place. This is strategic counsel, not just outreach.
When you need commercial strategy, not just leads
Commercial strategy answers what to sell, to whom and how to win, before any outreach starts. It is the layer above lead generation. You need it when growth has stalled, when revenue depends on too few clients, when you are entering the US or UK for the first time, or when you are preparing for a funding round or a sale and need a credible commercial story.
What chief commercial advisory covers
-
Commercial model and growth strategy design
-
Client portfolio diversification and concentration risk reduction
-
Market entry strategy for the US, UK and Europe
-
Positioning, value proposition and pricing direction
-
Ideal client profile and segment prioritisation at portfolio level
-
Commercial readiness for funding rounds, partnerships or exit
Why a PharmD-led, sector-specific view matters
Corstrate is led by Imen Jelassi, PharmD, with 17 years in life sciences commercial roles. Strategy in this market only works when it understands the science, the regulatory context and how scientific buyers actually decide. Generic commercial consultants miss this.
How this connects to execution
Once the strategy is set, Corstrate can execute it through lead generation, a fractional model, or conference meeting generation. Strategy first, then execution, in one place.
FAQ Section
What is the difference between commercial strategy and lead generation?
Lead generation executes outreach. Commercial strategy decides what to sell, to whom and how to win, before outreach begins.
How do you help diversify a client portfolio?
We map concentration risk, define new priority segments and markets, then design the commercial approach to reach them.
Do you also execute, or only advise?
Both. We can advise only, or move into execution through lead generation, fractional BD or conference meeting generation.